PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization approval of Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibod ...

Bristol-Myers Squibb Company (BMY) is scheduled to report fourth-quarter 2023 results on Feb 2, before market open.The company’s shares have lost 20.7% in the past six months compared with the industry's 0.3% growth.Image Source: Zacks Investment ResearchBristol-Myers beat earnings estimates in three of the last four quarters and missed once, the average surprise being 2.89%. In the previously reported quarter, the company beat estimates by 13.64%.Factors at PlayTotal revenues in the fourth quarter are like ...

PM Images It was another good week in the markets as the S&P 500 increased by 1.52% and the Nasdaq jumped 2.53%. The University of Michigan's consumer sentiment report increased to 78.8, which is the highest level since July of 2021. Technology led the markets higher as Taiwan Semiconductor (TSMC) announced a better-than-expected forecast that fueled the narrative around artificial intelligence. The U.S. economic data will be front and center next week as everyone will be looking for Q4 GDP growth estim ...

With the S&P 500 reaching new highs last week, investors appear to be taking an optimistic view of the overall stock market. However, not all stocks are participating in this rally. Some high-quality companies are still trading at beaten-down valuations, making them attractive value plays for investors. As monetary policy continues shifting in a more dovish direction, we could be at an inflection point where these value stocks start to regain their previous luster.That’s why I think now is an opportune time ...

After eight-straight monthly losses starting in April 2023, the shares of pharmaceutical concern Bristol-Meyers Squibb Co (NYSE:BMY) started to rebound in December, though were swiftly rejected by the 80-day moving average at the start of the year. Now, it looks like that bounce was indeed short-lived, as BMY is seeing even more pressure on the charts after its recent dip. According to Schaeffer's Senior Quantitative Analyst Rocky White, Bristol-Meyers stock is within one standard deviation of its 50-day an ...

The FDA has asked Gilead Sciences, Inc. (GILD) , Johnson & Johnson (JNJ) and Novartis (NVS) to add “boxed warning” to the labels of their chimeric antigen receptor (CAR) T-cell immunotherapies, per Reuters.The regulatory body sent letters to these companies stating that it had identified adverse events and clinical trial reports describing T-cell malignancies.We remind readers that in November 2023, the FDA announced that it was investigating the identified risk of T-cell malignancy in patients who received ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a wholly owned subsidiary of Bristol Myers Squibb. “The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipeline in ...

Parradee Kietsirikul Introduction Last year, we saw an uptick in M&A from big pharma to combat the significant drug patent cliff later in the decade. Amongst the worst anticipated patents cliffs is Bristol Myers Squibb (NYSE:BMY) who announced a number of deals into the end of 2023. Last year former COO and now current CEO Chris Boerner revised the $10bn-13bn sales target for new drugs by 2025 to $10bn by 2026, raising concerns over the company ability to completely offset patent loss in later years. Op ...

Bristol Myers Squibb (BMY) closed at $49.57 in the latest trading session, marking a -1.08% move from the prior day. This change lagged the S&P 500's 0.22% gain on the day. Meanwhile, the Dow experienced a rise of 0.36%, and the technology-dominated Nasdaq saw an increase of 0.32%.Shares of the biopharmaceutical company have depreciated by 4.17% over the course of the past month, underperforming the Medical sector's gain of 2.3% and the S&P 500's gain of 1.61%.The upcoming earnings release of Bristol Myers ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28% in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) vs. sunitinib after eight years, regardless of International Metastatic RCC Database Consortium (IMDC) risk group. Patients treated with Opdivo plus Yervoy maintained su ...